Florida Cancer Specialists Presents Real-World Evidence Studies on Blood Cancers at SOHO 2025
Key Insights
Florida Cancer Specialists & Research Institute (search) presented four abstracts at the Society for Hematologic Oncology (search) 2025 annual meeting, showcasing real-world evidence studies on myelofibrosis (search) and myelodysplastic syndromes (search).
The research includes a retrospective analysis of baseline clinical factors impacting overall survival in myelofibrosis (search) patients and treatment patterns for luspatercept in lower-risk myelodysplastic syndromes (search).
FCS operates more than 150 active clinical trials and has participated in studies for the majority of new cancer drugs approved in the U.S. prior to FDA approval.
Florida Cancer Specialists & Research Institute (search) (FCS) showcased its clinical expertise and real-world evidence capabilities at the Society for Hematologic Oncology (search) (SOHO) 2025 annual meeting in Houston, presenting four research abstracts focused on advancing treatment of hematologic malignancies (search).
Real-World Evidence Studies Lead FCS Presentations
Amanda Warner, MS, RN, FCS Director of Real-World Evidence, served as presenting author for two key studies. The first, titled "Myelofibrosis (search) Observational Real-World Experience in Community Oncology (MORE-CO): A Retrospective Analysis of Baseline Clinical Factors Impacting Overall Survival," was co-authored by Lucio N. Gordan, MD, Arsh Singh, MD, and Trevor Heritage, PhD.
The second study examined "Real-World Treatment Patterns and Outcomes of Luspatercept in Treatment-Naïve Patients with Lower-Risk Myelodysplastic Syndromes (search) (LR-MDS) in a Large Community Oncology Practice," with co-authors Gustavo Fonseca, MD, FACP, and Christian Okitondo, PhD.
Advanced Clinical Research Portfolio
FCS President & Managing Physician Lucio N. Gordan, MD, emphasized the organization's comprehensive approach: "By combining the care of more than one million patients with our deep clinical, research, and informatics expertise, we are driving meaningful advances in understanding blood cancers and accelerating the development of new therapies."
Additional research presentations featured FCS participation in innovative treatment approaches, including a Phase 2 study of subcutaneous isatuximab administered by an on-body delivery system with weekly carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma (search), co-authored by Alexander Philipovskiy, MD, PhD. The organization also contributed to preliminary insights into CAR-T therapy for melanoma (search) through a systematic review co-authored by Uma Iyer, MD.
Data Science Infrastructure Drives Clinical Insights
Trevor Heritage, PhD, FCS clinical technology director, highlighted the organization's technological investments: "FCS in recent years has made forward-thinking investments in proprietary real-world datasets and advanced data science. Our comprehensive approach transforms real-world clinical data into high-quality insights that are driving improvements in clinical decision making, closing gaps in care, and enhancing patient experiences and outcomes."
Extensive Clinical Trial Network
FCS maintains more than 150 active clinical trials at any given time, including early-phase studies conducted at three drug development units. The organization's research capabilities are enhanced through partnerships with Sarah Cannon Research Institute (search) and Paradigm Health (search), an AI-enabled clinical trial matching and recruitment platform.
According to FCS, the majority of new cancer drugs approved for use in the United States were studied in clinical trials with FCS participation prior to receiving FDA approval, positioning the organization as a leader in research among private oncology practices in Florida and nationally.